Update in Clinical Psychopharmacology Peter A. DeMaria, Jr., M.D., FASAM, DFAPA Tuttleman Counseling Services Temple University Clinical Professor of Psychiatry & Behavioral Sciences Temple University School of Medicine Philadelphia, PA Disclosures • I am a treatment advocate for Reckitt-Benkiser Pharmaceutical Co.. • Use of trade versus generic drug names • Off-label use of drugs. • Role of counseling/psychotherapy Website: https://sites.google.com/site/achapsychopharmacology/ Case A - Alisha Alisha is a 19 y/o sophomore student who presents for follow-up. A month ago she was diagnosed with major depression and started on citalopram 20 mg daily. She reports that she is tolerating the medication without side effects and has started to feel better but still has crying spells, difficulty with sleep low energy and is increasingly worried about completing her academically demanding schedule. Evaluating a Response to Antidepressant Medication • Is the patient taking it? – Ambivalence/stigma towards medication – Parental pressure to avoid medication – Availability (insurance, cost) • Is it the right: – Drug? – Dose? – Length of time? • Are there co-morbid conditions? Case A – Alisha (Part 2) Alisha reports that she got the medication and assures you that she has been compliant. You review the time course of response and recommend that she increase the dose to 40 mg to optimize her response to treatment. Additionally, you ask if she has been able to connect with the counseling center. She tells you that she has an intake appointment in the next week. Case A – Alisha (Part 3) (One month later; 2 months on citalopram) Alisha returns for her follow-up visit. She has been taking citalopram 40 mg daily and thinks it might be making her tired. She connected with a therapist at the counseling center and likes her. Alisha still reports decreased energy and feeling down. Her relationship with her partner has deteriorated and she is having thoughts of cutting herself. She denies SI. STAR*D • Largest (n=4041, age 18-75 y/o) study of treatment of non-psychotic MDD • Multiple real-world psychiatric and primary care settings • Conducted between July 2001 and April 2004 • Funded by National Institute of Mental Health (NIMH) • Goal was remission (< 5 on the QIDS-C16) • Treatment involved 6 levels with patient ability to choose options • Available at www.star-d.org STAR*D • MDD is a chronic and recurrent illness. • Using objective measurements of symptoms and side effects can help with treatment decisions. • Remission can take time (at least 8, but up to 14 weeks). • Many steps may be needed to reach remission. – Level 1 (citalopram @ 8 wks.): Remission = 37%, Response = 49% – Remission rate of 50% was reached after 2 steps. – Remission rate of 70% was reached after 4 steps • Remission results in better log-term outcomes. • Participant attrition is high. (Warden D et al. The STAR*D project results: a comprehensive review of findings. Current Psychiatry Reports 9:449-459, 2007.) Treatment Options for Non-Responsive MDD • Optimize dose and treatment time • Add psychotherapy • In-class switch (e.g. SSRI → SSRI) • Between class switch (e.g. SSRI → SNRI/other agent) • Augment • Brain stimulation Augmentation Strategies in Treating Major Depression • • • • • Add a second AD with a different MOA L-Methylfolate (7.5 - 15 mg/day) T3 (5 - 50 mcg) Lithium Atypical antipsychotic – Aripiprazole (2 – 15 mg/day) – Quetiapine XR (50 – 300 mg/day) • Supplements (?) – Omega-3-fatty acids – SAMe (1600 mg/day) – Creatine (5 gm/day) Vilazodone (Viibryd) • • • • • • • • MOA: SSRI and partial5-HT1A agonist Metabolism: P450 CYP 3A4 FDA Approval: Major depression Efficacy demonstrated compared to placebo; no head-to-head trial with other AD. Separates from placebo at one week (?). Side effects: diarrhea. Insomnia, dizziness Dosing: Start with 10 mg increase weekly to 20 mg then 40 mg. Take with food Benefits(?): low sexual dysfunction, no weight gain Focal Brain Stimulation • Vagal Nerve Stimulation (VNS) – Pulse generator implanted in the left chest wall – Electrode wrapped around the left vagus nerve – Pulse on for 30 seconds and off for 5 minutes – Efficacy = ? • Transcranial magnetic stimulation (TMS) – Uses an electromagnetic coil placed against the scalp to create a rapidly changing magnetic field that depolarizes neurons. – Outpatient procedure – Safe and well tolerated – Efficacy =? On the Horizon • Starting 2 versus 1agent at treatment initiation • NMDA receptor antagonists (ketamine) • Corticotropin releasing factor-1 (CRF1) antagonists • Glucocorticoid receptor antagonists • Substance P receptor antagonists • Melanocyte inhibiting factor (nemifitide) • Melatonin receptor antagonists • Focal and deep brain stimulation therapies Case B - Nicole Nicole is a 21 y/o junior who presents complaining of panic attacks and anxiety. In talking with her, she states that she feels no one likes her and she is just a failure. She worries about her family and her dying grandmother. Her sleep is poor and she has lost interest in food. She isn’t interested in her school work and wonders if she would just be better off dead. Differential Diagnosis of “Anxiety” • • • • • • • Secondary to a medical condition Substance induced Major depression Mania/hypomania Psychotic disorder Personality disorder Anxiety disorder Anxiety is a non-specific symptom; Need to determine the cause DSM-IV vs. DSM-5 DSM-!V • Anxiety Disorders – – – – – – – Specific phobia Panic disorder Social phobia OCD PTSD Acute stress Generalized anxiety disorder • Adjustment disorders DSM-5 • Anxiety Disorders – – – – Specific phobia Social anxiety disorder Panic disorder Generalized anxiety disorder • O-C & Related Disorders – OCD • Trauma & Stressor Related Disorders – PTSD – Acute stress disorder – Adjustment disorder Pharmacologic Treatments • • • • Benzodiazepines SSRI/SNRI Tricyclic antidepressants Other agents J of Clin. Psychiatry, 60(5), 252, May 1999 FDA Approved Indications MDD PD OCD SP PTSD GAD PMDD BN ND FM SSRI Citalopram (Celexa) X Escitalopram (Lexapro) X X Fluoxetine (Prozac) X X X X X Fluvoxamine (Luvox) X Paroxetine (Paxil/CR) X X X X X X X Sertraline (Zoloft) X X X X X X SNRI Desvenlafaxine (Pristiq) X Duloxetine (Cymbalta) X X X Mirtazapine (Remeron) X Venlafaxine (Effexor/XL) X X X X Tricyclic Antidepressant Clomipramine (Anafranil) X Other Bupropion (Wellbutrin) X X Buspirone (BuSpar) X Vilazodone (Viibryd) X SSRI/SNRIs in Anxiety Disorders Advantages • High efficacy • Non-addicting • Effective for a number of conditions Disadvantages • Can take 2-8 weeks or longer to be effective • Side effects • Drug interactions • Discontinuation syndrome Other Options for Anxiety Disorders • • • • • Buspirone Beta blockers (e.g. propranolol) Tricyclic antidepressants Vilazodone (SSRI/5-HT1A Partial agonist) Antipsychotics • Typical (e.g. Trifluoperazine) • Atypical (e.g. Quetiapine) • Antihistamines • Hydroxyzine • Anticonvulsants • Gabapentin/Pregabalin • Combinations Psychotropic Choice for Specific Conditions Condition Pharmacotherapy Options Obsessive compulsive disorder SSRI Clomipramine Social anxiety disorder SSRI/SNRI Panic disorder SSRI TCA Benzodiazepine SSRI PTSD Generalized anxiety disorder SSRI/SNRI Benzodiazepine Buspirone Case C - Marc Marc is a 22 y/o junior who presents requesting a refill of his medication. He tells you he was diagnosed with bipolar disorder and ADHD and is currently prescribed: lamotrigine 200 mg daily, escitalopram 10 mg daily, clonazepam 1 mg BID, zolpidem 5 mg HS, and Adderall-XR 20 mg qAM. Bipolar disorder vs. Bipolar spectrum disorder • Definition – Spectrum disorder • Epidemiology (lifetime prevalence) – Bipolar I disorder = 1% – Bipolar spectrum disorders = 2.6 – 6.5% • Delayed diagnosis/missed diagnosis – Screen depressed patients for possible bipolar depression (e.g. MDQ, BSRS) Mood Disorders – A Spectrum Disease "Normal" Mania Hypomania Euthymia Dysthymia Major depression Bipolar I Disorder Bipolar II Disorder Major depression Cyclothymia Dysthymia Borderline Personality Disorder The Heterogeneity of Bipolar Disorder Taken from: http://www.psychosisbipolar.com/information-aboutpsychoses-57.htmlTaken Lifetime Comorbidity with Bipolar Disorder Disorder Class Anxiety Disorders Panic disorder PTSD GAD SAD ADHD Substance Use Disorders Alcohol abuse Alcohol dependence Drug abuse Drug dependence Comorbidity (%) 20.1 24.2 29.6 35.4 31.4 39.1 23.2 28.8 34.0 Treating Bipolar Disorder • Use mood charting. • Combination pharmacotherapy is the rule rather than the exception. • Mood stabilizers are the cornerstone of therapy. • Optimize therapeutic effect and tolerability while minimizing side effects. • Antidepressants may worsen the disease course. Pharmacotherapy for Mood Disorders 1. Mood stabilizers Lithium 2. Anticonvulsant Mood Stabilizers Valproic acid (Depakote) Carbamazepine (Tegretol) Lamotrigine (Lamictal) 3. Atypical Antipsychotics See Chart 4. Combination Olanzapine/fluoxetine (Symbyax) FDA Approved Indications for Atypical Antipsychotics Indication Schizophrenia OLA RIS ILO QUE ZIP ARI ASEN LUR X X X X X X X X X X X X Schizoaffective Disorder X Bipolar Mania/Mixed X X Bipolar Depression X X Adjunct in MDD X X X X OLA = Olanzapine, RIS = Risperidone, ILO = Iloperidone, QUE = Quetiapine, ZIP = Ziprasidone, ARI = Aripiprazole, ASEN = Asenapine, LUR lurasidone Pharmacotherapy for Bipolar Disorder Phase Mania Depression Maintenance Treatment Options Lithium (Li) Valproate (VP) Atypical antipsychotic Carbamazepine/oxcarbamazepine Li/VP + atypical antipsychotic Electroconvulsive therapy (ECT) Optimize mood stabilizer Lamotrigine Quetiapine Lurasidone Olanzapine/fluoxetine Mood stabilizer + antidepressant In general, continue regimen that is working, however, simplify as clinically indicated. Questions?